Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/50236
DC FieldValueLanguage
dc.contributor.authorBende, Matsen_US
dc.contributor.authorCarrillo, Teresaen_US
dc.contributor.authorVóna, Idaen_US
dc.contributor.authorDa Graça Castel-Branco, Mariaen_US
dc.contributor.authorArheden, Larsen_US
dc.date.accessioned2018-11-24T14:28:04Z-
dc.date.available2018-11-24T14:28:04Z-
dc.date.issued2002en_US
dc.identifier.issn1081-1206en_US
dc.identifier.urihttp://hdl.handle.net/10553/50236-
dc.description.abstractBackground Using conventional methods, it has been difficult to show differences in efficacy between intranasal corticosteroids in perennial rhinitis. Objective To compare the effects of budesonide and mometasone on nasal symptoms and nasal airflow in perennial allergic rhinitis. Methods Four hundred thirty-eight patients (age >18 years old) were randomized to budesonide, 256 μg or 128 μg, mometasone furoate 200 μg, or placebo, once daily for 4 weeks. Efficacy was evaluated by nasal index score (NIS; the sum of scores for blocked nose, runny nose, and itchy nose/sneezing) and peak nasal inspiratory flow (PNIF). Results All three active treatments significantly reduced the NIS compared with placebo. There was no significant difference between the treatments, although the effect of budesonide, 256 μg, tended to be greater than that of the other regimens. PNIF was significantly improved with all three active treatments: the effect of budesonide 256 μg on morning and evening PNIF was significantly greater than that of mometasone furoate and 128 μg budesonide. Budesonide had a rapid onset of action, showing a significantly greater effect on evening PNIF than mometasone furoate during the first 10 days. For all active treatments, significant improvements in NIS were seen within 4 hours of the first dose. All three treatments were well tolerated. Conclusion The objective parameter PNIF was capable of demonstrating greater efficacy of budesonide 256 μg compared with budesonide 128 μg and mometasone furoate 200 μg, whereas the combined nasal symptom score could only distinguish active treatment from placebo.en_US
dc.languageengen_US
dc.relation.ispartofAnnals of Allergy, Asthma and Immunologyen_US
dc.sourceAnnals of Allergy, Asthma and Immunology[ISSN 1081-1206],v. 88, p. 617-623 (Junio 2002)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320701 Alergiasen_US
dc.subject.otherClinical trialen_US
dc.subject.otherRandomized controlled trialen_US
dc.subject.otherBudesonideen_US
dc.subject.otherInspiratory capacityen_US
dc.subject.otherMometasone furoateen_US
dc.subject.otherPregnadienediolsen_US
dc.titleA randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitisen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/S1081-1206(10)61894-7en_US
dc.identifier.scopus0036627699-
dc.contributor.authorscopusid7006668474-
dc.contributor.authorscopusid7003526269-
dc.contributor.authorscopusid24077468200-
dc.contributor.authorscopusid6505449996-
dc.contributor.authorscopusid6506758662-
dc.description.lastpage623en_US
dc.description.firstpage617en_US
dc.relation.volume88en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages7en_US
dc.utils.revisionen_US
dc.date.coverdateJunio 2002en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.jcr1,67-
dc.description.jcrqQ3-
dc.description.scieSCIE-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR Patología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameCarrillo Díaz, Teresa-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

53
checked on Jun 26, 2022

Page view(s)

18
checked on Jun 12, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.